Hypermarcas (OTCMKTS:HYPMY) Shares Gap Down - Should You Sell?

Key Points

• Hypermarcas shares gapped down to $4.41 at the start of trading, down from a previous close of $4.64, with a trading volume of 469 shares.
• Scotiabank has upgraded Hypermarcas to a "strong-buy" rating, contributing to an average rating of "Strong Buy" among analysts.
• The company recently declared a dividend of $0.0345, which represents an impressive yield of 281.0%, set to be paid on January 8th.

Shares of Hypermarcas (OTCMKTS:HYPMY - Get Free Report) gapped down before the market opened on Thursday . The stock had previously closed at $4.64, but opened at $4.41. Hypermarcas shares last traded at $4.41, with a volume of 469 shares trading hands.

Analyst Upgrades and Downgrades

Separately, Scotiabank upgraded shares of Hypermarcas to a "strong-buy" rating in a research note on Thursday, July 17th. One investment analyst has rated the stock with a Strong Buy rating, Based on data from MarketBeat, the company currently has a consensus rating of "Strong Buy".

Hypermarcas Trading Down 1.6%

The company has a quick ratio of 0.80, a current ratio of 1.26 and a debt-to-equity ratio of 0.63. The firm's 50 day simple moving average is $4.45 and its two-hundred day simple moving average is $4.20. The stock has a market cap of $2.87 billion, a P/E ratio of 21.55 and a beta of 0.86.

Hypermarcas (OTCMKTS:HYPMY - Get Free Report) last released its earnings results on Wednesday, August 6th. The company reported $0.12 earnings per share for the quarter. Hypermarcas had a net margin of 11.28% and a return on equity of 6.19%.

Hypermarcas Announces Dividend

The company also recently declared a dividend, which will be paid on Friday, January 8th. Stockholders of record on Tuesday, July 1st will be issued a dividend of $0.0345 per share. The ex-dividend date of this dividend is Monday, June 30th. This represents a dividend yield of 281.0%. Hypermarcas's payout ratio is 57.14%.

Hypermarcas Company Profile

Hypera SA operates as a pharmaceutical company in Brazil. It offers prescription products under the Adacne, Addera, apri, AmpliumG, please, Celestamine, Celestone, Celestone Soluspan, Cizax, deciprax, Derive C Micro, Micro Drift, Dermotil Fusid, Digedrat, diprogent, Diprosalic, Diprosone, diprospan, Emprol XR, Flow, Garasone, Halobex, Lipanon, moon, Lydian, macrodantin, Max Sulid, milgamma, Mioflex A, nesina, Novotram, oximax, peridal, Peridal Suspension, PredSim, Pressaliv, Quadriderm, Rizi, Rizi M, softalm, tacroz, tinodin, umma, and velunid brands.